{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:03:26Z","timestamp":1788469406742,"version":"build-2803163510"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bioorg.2024.108073","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T20:00:21Z","timestamp":1734379221000},"page":"108073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeting XPO1 for fighting relapsed\/refractory diseases: The research progress of XPO1 inhibitors"],"prefix":"10.1016","volume":"154","author":[{"given":"Ye-Qin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Wu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bioorg.2024.108073_b0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioorg.2024.108073_b0010","doi-asserted-by":"crossref","unstructured":"R.A. Kyle, S.V. Rajkumar, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma, Leukemia. 23 (2009) 3-9, https:\/\/doi.org\/ 10.1038\/leu.2008.291.","DOI":"10.1038\/leu.2008.291"},{"key":"10.1016\/j.bioorg.2024.108073_b0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-022-01319-y","article-title":"Oral Eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents","volume":"15","author":"Lee","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2020","key":"10.1016\/j.bioorg.2024.108073_b0020","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma, update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bioorg.2024.108073_b0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2024.108073_b0030","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108073_b0035","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bioorg.2024.108073_b0040","doi-asserted-by":"crossref","unstructured":"R.F. Cornell, A.A. Kassim, Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity, Bone Marrow Transplantation, 51 (2016) 479-491, https:\/\/doi.org\/ 10.1038\/bmt.2015.307.","DOI":"10.1038\/bmt.2015.307"},{"key":"10.1016\/j.bioorg.2024.108073_b0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.108073_b0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.critrevonc.2017.02.007","article-title":"How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients","volume":"112","author":"Sonneveld","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2024.108073_b0055","doi-asserted-by":"crossref","unstructured":"B. Galinski, M. Luxemburg, Y. Landesman, B. Pawel, K.J. Johnson, S.R. Master, et al. XPO1 inhibition with Selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB, Transl Oncol, 14 (2021) 101114, https:\/\/doi.org\/ 10.1016\/j.tranon.2021.101114.","DOI":"10.1016\/j.tranon.2021.101114"},{"key":"10.1016\/j.bioorg.2024.108073_b0060","doi-asserted-by":"crossref","unstructured":"Y.T. Tai, Y. Landesman, C. Acharya, Y. Calle, M.Y. Zhong, M. Cea, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications, Leukemia, 28 (2014) 155-165, https:\/\/doi.org\/ 10.1038\/leu.2013.115.","DOI":"10.1038\/leu.2013.115"},{"key":"10.1016\/j.bioorg.2024.108073_b0065","doi-asserted-by":"crossref","unstructured":"H.Y. Fung, Y.M. Chook, Atomic basis of CRM1-cargo recognition, release and inhibition, Semin Cancer Biol, 27 (2014) 52-61, https:\/\/doi.org\/ 10.1016\/j.semcancer.2014.03.002.","DOI":"10.1016\/j.semcancer.2014.03.002"},{"key":"10.1016\/j.bioorg.2024.108073_b0070","doi-asserted-by":"crossref","unstructured":"D. Xu, N.V. Grishin, Y.M. Chook, NESdb: a database of NES-containing CRM1 cargoes, Mol Biol Cell, 23 (2012) 3673-3676, https:\/\/doi.org\/ 10.1091\/mbc.E12-01-0045.","DOI":"10.1091\/mbc.e12-01-0045"},{"key":"10.1016\/j.bioorg.2024.108073_b0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.bioorg.2024.108073_b0080","doi-asserted-by":"crossref","unstructured":"J.G. Turner, T. Kashyap, J.L. Dawson, J. Gomez, A.A. Bauer, S. Grant, et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkBa and overcomes acquired proteasome inhibitor resistance in human multiple myeloma, Oncotarget, 7 (2016) 78896-78909, https:\/\/doi.org\/ 10.18632\/oncotarget.12969.","DOI":"10.18632\/oncotarget.12969"},{"issue":"10","key":"10.1016\/j.bioorg.2024.108073_b0085","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.drudis.2020.06.014","article-title":"Exportin 1 inhibition as antiviral therapy","volume":"25","author":"Uddin","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bioorg.2024.108073_b0090","unstructured":"M.M. Rahman, B. Estifanos, H.L. Glenn, K. Kibler, Y. Li, B. Jacobs, et al. Nuclear export inhibitor Selinexor targeting XPO1 enhances coronavirus replication, bioRxiv [Preprint]. 2023 Feb 13:2023.02.09.527884, https:\/\/doi.org\/ 10.1101\/2023.02.09.527884."},{"key":"10.1016\/j.bioorg.2024.108073_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105115","article-title":"Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo","volume":"192","author":"Kashyap","year":"2021","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41419-020-03303-1","article-title":"Targeting XPO1 enhances innate immune response and inhibits KSHV lytic replication during primary infection by nuclear stabilization of the p62 autophagy adaptor protein","volume":"12","author":"Meng","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2024.108073_b0105","doi-asserted-by":"crossref","unstructured":"C. Mathew, S. Tamir, R.A. Tripp, R. Ghildyal, Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication. 11(1) (2021):19223, https:\/\/doi.org\/10.1038\/s41598-021-98767-2.","DOI":"10.1038\/s41598-021-98767-2"},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0110","doi-asserted-by":"crossref","first-page":"e01684","DOI":"10.1128\/JVI.01684-18","article-title":"Verdinexor (KPT-335), a Selective Inhibitor of Nuclear Export, Reduces Respiratory Syncytial Virus Replication In Vitro","volume":"93","author":"Jorquera","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2024.108073_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.675112","article-title":"The Second-Generation XPO1 Inhibitor Eltanexor Inhibits Human Cytomegalovirus (HCMV) Replication and Promotes Type I Interferon Response","volume":"12","author":"Liao","year":"2021","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bioorg.2024.108073_b0120","doi-asserted-by":"crossref","unstructured":"E.L 3rd. Evans, J.T. Becker, S.L. Fricke, K. Patel, N.M. Sherer, HIV-1 Vif's Capacity to Manipulate the Cell Cycle Is Species Specific. J Virol. 92(7) (2018) e02102-17, https:\/\/doi.org\/10.1128\/JVI.02102-17.","DOI":"10.1128\/JVI.02102-17"},{"issue":"3","key":"10.1016\/j.bioorg.2024.108073_b0125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1101\/gr.276407.121","article-title":"Global loss of cellular m6A RNA methylation following infection with different SARS-CoV-2 variants","volume":"33","author":"Vaid","year":"2023","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13578-021-00567-8","article-title":"Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment","volume":"11","author":"Zhu","year":"2021","journal-title":"Cell Biosci."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108073_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01325-23","article-title":"4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1","volume":"97","author":"Rib\u00f3-Molina","year":"2023","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.108073_b0140","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/2767-9764.CRC-22-0483","article-title":"Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer","volume":"3","author":"Rahman","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bioorg.2024.108073_b0145","doi-asserted-by":"crossref","unstructured":"A. Yasunaga, S.L. Hanna, J. Li, H. Cho, P.P. Rose, A. Spiridigliozzi, et al. Genome-wide RNAi screen identifies broadly-acting host factors that inhibit arbovirus infection, PLoS Pathog. 10(2) (2014) e1003914, https:\/\/doi.org\/ 10.1371\/journal.ppat.1003914.","DOI":"10.1371\/journal.ppat.1003914"},{"key":"10.1016\/j.bioorg.2024.108073_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198504","article-title":"Effects of CRM1-dependent nuclear export inhibition on viral structural protein nuclear accumulation during Autographa californica multiple nucleopolyhedrovirus infection","volume":"303","author":"Hu","year":"2021","journal-title":"Virus Res."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108073_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01273-21","article-title":"CRM1 Promotes Capsid Disassembly and Nuclear Envelope Translocation of Adenovirus Independently of Its Export Function","volume":"F96","author":"Lagadec","year":"2022","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/v8080209","article-title":"NXT1, a Novel Influenza A NP Binding Protein, Promotes the Nuclear Export of NP via a CRM1-Dependent Pathway","volume":"8","author":"Chutiwitoonchai","year":"2016","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0165","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00430-012-0269-7","article-title":"Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65","volume":"201","author":"Frankenberg","year":"2012","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.bioorg.2024.108073_b0170","doi-asserted-by":"crossref","unstructured":"L. Lundberg, C. Pinkham, C. de la Fuente, A. Brahms, N. Shafagati, K.M. Wagstaff, et al. Selective Inhibitor of Nuclear Export (SINE) Compounds Alter New World Alphavirus Capsid Localization and Reduce Viral Replication in Mammalian Cells, PLoS Negl Trop Dis. 10(11) (2016) e0005122, https:\/\/doi.org\/ 10.1371\/journal.pntd.0005122.","DOI":"10.1371\/journal.pntd.0005122"},{"issue":"23","key":"10.1016\/j.bioorg.2024.108073_b0175","doi-asserted-by":"crossref","first-page":"15589","DOI":"10.1074\/jbc.M808271200","article-title":"CRM1-mediated nuclear export of dengue virus RNA polymerase NS5 modulates interleukin-8 induction and virus production","volume":"284","author":"Rawlinson","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108073_b0180","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1074\/jbc.M115.706135","article-title":"HIV-1 Nef-associated Factor 1 Enhances Viral Production by Interacting with CRM1 to Promote Nuclear Export of Unspliced HIV-1 gag mRNA","volume":"291","author":"Ren","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2024.108073_b0185","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.1128\/JVI.00692-12","article-title":"Feline immunodeficiency virus Gag is a nuclear shuttling protein","volume":"86","author":"Kemler","year":"2012","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.bioorg.2024.108073_b0190","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/cells8101181","article-title":"Exportin-1-Dependent Nuclear Export of DEAD-box Helicase DDX3X is Central to its Role in Antiviral Immunity","volume":"8","author":"Heaton","year":"2019","journal-title":"Cells."},{"issue":"16","key":"10.1016\/j.bioorg.2024.108073_b0195","doi-asserted-by":"crossref","first-page":"8940","DOI":"10.1128\/JVI.00633-13","article-title":"Role of immediate early protein ICP27 in the differential sensitivity of herpes simplex viruses 1 and 2 to leptomycin B","volume":"87","author":"Park","year":"2013","journal-title":"J. Virol."},{"issue":"19","key":"10.1016\/j.bioorg.2024.108073_b0200","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1073\/pnas.1319635111","article-title":"Drosha as an interferon-independent antiviral factor","volume":"111","author":"Shapiro","year":"2014","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.bioorg.2024.108073_b0205","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbrc.2004.06.174","article-title":"ZAP is a CRM1-dependent nucleocytoplasmic shuttling protein","volume":"321","author":"Liu","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108073_b0210","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/08892220050042792","article-title":"Rev protein of human immunodeficiency virus type 1 and cellular exportin 1 protein relocalize each other to a subnucleolar structure","volume":"16","author":"Ristea","year":"2000","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.bioorg.2024.108073_b0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.antiviral.2016.07.024","article-title":"Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins","volume":"134","author":"Jang","year":"2016","journal-title":"Antiviral Res."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0220","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1128\/JVI.06361-11","article-title":"Nuclear export and expression of human T-cell leukemia virus type 1 tax\/rex mRNA are RxRE\/Rex dependent","volume":"86","author":"Bai","year":"2012","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0225","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1074\/jbc.M408452200","article-title":"A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization","volume":"280","author":"Lin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0230","first-page":"e03514","article-title":"HBV Core Protein Is in Flux between Cytoplasmic","volume":"12","author":"Nair","year":"2021","journal-title":"Nuclear, and Nucleolar Compartments, mBio."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0235","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3390\/v13081650","article-title":"The Ebola Virus Interferon Antagonist VP24 Undergoes Active Nucleocytoplasmic Trafficking","volume":"13","author":"Harrison","year":"2021","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.bioorg.2024.108073_b0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010588","article-title":"RANBP2 and USP9x regulate nuclear import of adenovirus minor coat protein IIIa","volume":"18","author":"Ismail","year":"2022","journal-title":"PLoS Pathog."},{"issue":"22","key":"10.1016\/j.bioorg.2024.108073_b0245","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1128\/JVI.76.22.11476-11483.2002","article-title":"Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation","volume":"76","author":"Rodriguez","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.bioorg.2024.108073_b0250","doi-asserted-by":"crossref","unstructured":"L. Chen, Y. Huang, L. Zhou, Y. Lian, J. Wang, D. Chen, et al. Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma, Biosci Rep. 39(8) (2019) BSR20190827, https:\/\/doi.org\/ 10.1042\/BSR20190827.","DOI":"10.1042\/BSR20190827"},{"issue":"23","key":"10.1016\/j.bioorg.2024.108073_b0255","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood.V126.23.129.129","article-title":"Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study","volume":"126","author":"Jardin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108073_b0260","doi-asserted-by":"crossref","unstructured":"M. Nagasaka, M.F.B. Asad, M.N. Al Hallak, M.H. Uddin, A. Sukari, Y. Baca, et al. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC), Lung Cancer. 160(2021)92-98, https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.010.","DOI":"10.1016\/j.lungcan.2021.08.010"},{"key":"10.1016\/j.bioorg.2024.108073_b0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13048-015-0166-y","article-title":"Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer","volume":"8","author":"Liu","year":"2015","journal-title":"J Ovarian Res."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0270","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1535-7163.MCT-19-0977","article-title":"NRG1\/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors","volume":"19","author":"Miyake","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"13 Supplement","key":"10.1016\/j.bioorg.2024.108073_b0275","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/1538-7445.AM2017-1938","article-title":"Abstract 1938: Exportin-1 (XPO1) is a novel therapeutic biomarker for patients with neuroblastoma","volume":"77","author":"Galinski","year":"2017","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108073_b0280","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.bioorg.2024.108073_b0285","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.31557\/APJCP.2019.20.12.3747","article-title":"Association of XPO1 Overexpression with NF-\u03baB and Ki67 in Colorectal Cancer","volume":"20","author":"Aladhraei","year":"2019","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"9","key":"10.1016\/j.bioorg.2024.108073_b0290","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","article-title":"Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma","volume":"91","author":"Jardin","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0295","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/CBM-160375","article-title":"A 80-gene set potentially predicts the relapse in laryngeal carcinoma optimized by support vector machine","volume":"19","author":"Yang","year":"2017","journal-title":"Cancer Biomark."},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0300","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.23354","article-title":"Expression of the nuclear export protein chromosomal region maintenance\/exportin 1\/Xpo1 is a prognostic factor in human ovarian cancer","volume":"112","author":"Noske","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2024.108073_b0305","doi-asserted-by":"crossref","unstructured":"Q. Huang, H. Guo, S. Wang, Y. Ma, H. Chen, H. Li, et al. A novel circular RNA, circXPO1, promotes lung adenocarcinoma progression by interacting with IGF2BP1, Cell Death Dis. 11(12)(2020) 1031, https:\/\/doi.org\/10.1038\/s41419-020-03237-8.","DOI":"10.1038\/s41419-020-03237-8"},{"issue":"7","key":"10.1016\/j.bioorg.2024.108073_b0310","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/14737159.2023.2224505","article-title":"Clinicopathological and prognostic significance of XPO1 in solid tumors: meta-analysis and TCGA analysis","volume":"23","author":"Tan","year":"2023","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108073_b0315","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3906\/biy-1711-8","article-title":"Crm1 knockdown by specific small interfering RNA reduces cell proliferation and induces apoptosis in head and neck cancer cell lines","volume":"42","author":"\u00d6zda\u015f","year":"2018","journal-title":"Turk. J. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0320","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s12032-013-0726-1","article-title":"CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas","volume":"30","author":"Zhou","year":"2013","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0325","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jcmm.17667","article-title":"Protein biomarkers for response to XPO1 inhibition in haematologic malignancies","volume":"27","author":"Totiger","year":"2023","journal-title":"J. Cell Mol. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108073_b0330","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Yoshimura","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2024.108073_b0335","doi-asserted-by":"crossref","unstructured":"A.Y. Wang, H. Liu. The past, present, and future of CRM1\/XPO1 inhibitors, Stem Cell Investig. 6(2019) 6. https:\/\/doi.org\/10.21037\/sci.2019.02.03.","DOI":"10.21037\/sci.2019.02.03"},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0340","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Newlands","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2024.108073_b0345","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"Parikh","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.108073_b0350","unstructured":"K. Therapeutics, This label may not be the latest approved by FDA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212306s001lbl.pdf, 2020."},{"issue":"2","key":"10.1016\/j.bioorg.2024.108073_b0355","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.18632\/oncotarget.6495","article-title":"A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds","volume":"7","author":"Crochiere","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0360","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108073_b0365","doi-asserted-by":"crossref","unstructured":"Z.A. Hing, H.Y. Fung, P. Ranganathan, S. Mitchell, D. El-Gamal, J.A. Woyach, et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies, Leukemia. 30 (2016) 2364-2372, https:\/\/doi.org\/ 10.1038\/leu.2016.136.","DOI":"10.1038\/leu.2016.136"},{"key":"10.1016\/j.bioorg.2024.108073_b0370","doi-asserted-by":"crossref","unstructured":"T. Vercruysse, J. De Bie, J.E. Neggers, M. Jacquemyn, E. Vanstreels, J.L. Schmid-Burgk, et al. The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia, Clin Cancer Res, 23 (2017) 2528\u20132541, https:\/\/doi.org\/ 10.1158\/1078-0432.CCR-16-1580.","DOI":"10.1158\/1078-0432.CCR-16-1580"},{"key":"10.1016\/j.bioorg.2024.108073_b0375","doi-asserted-by":"crossref","unstructured":"J. Etchin, A. Berezovskaya, A.S. Conway, I.A. Galinsky, R.M. Stone, E. Baloglu, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells, Leukemia. 31 (2017) 143-150, https:\/\/doi.org\/ 10.1038\/leu.2016.145.","DOI":"10.1038\/leu.2016.145"},{"key":"10.1016\/j.bioorg.2024.108073_b0380","article-title":"Anti-Osteoclast Effect of Exportin-1 Inhibitor Eltanexor on Osteoporosis Depends on Nuclear Accumulation of I\u03baB\u03b1-NF-\u03baB p65 Complex","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.108073_b0385","doi-asserted-by":"crossref","unstructured":"H. Takeuchi, H. Mizoguchi, F. Tanaka, A. Suzumura, GAP junction\/hemichannel blockers ameliorate the disease progression of FTLD\/ALS mice, Journal of the Neurological Sciences. 381 (2017) 714-715, https:\/\/doi.org\/ 10.1016\/j.jns.2017.08.2013.","DOI":"10.1016\/j.jns.2017.08.2013"},{"key":"10.1016\/j.bioorg.2024.108073_b0390","doi-asserted-by":"crossref","unstructured":"J.C. Grima, J.G. Daigle, N. Arbez, K.C. Cunningham, K. Zhang, J. Ochaba, et al. Mutant Huntingtin Disrupts the Nuclear Pore Complex, Neuron. 94 (2017) 93-107 e106, https:\/\/doi.org\/ 10.1016\/j.neuron.2017.03.023.","DOI":"10.1016\/j.neuron.2017.03.023"},{"key":"10.1016\/j.bioorg.2024.108073_b0395","doi-asserted-by":"crossref","unstructured":"D. Cantu, D. Croker, S. Shacham, S. Tamir, C. Dulla, In vivo KPT-350 treatment decreases cortical hyperexcitability following traumatic brain injury, Brain Injury. 34 (2020) 1489-1496, https:\/\/doi.org\/ 10.1080\/02699052.2020.1807056.","DOI":"10.1080\/02699052.2020.1807056"},{"key":"10.1016\/j.bioorg.2024.108073_b0400","doi-asserted-by":"crossref","unstructured":"S. Wang, X. Han, J. Wang, J. Yao, Y. Shi, Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts, PLoS One. 9 (2014) e89848, https:\/\/doi.org\/ 10.1371\/journal.pone.0089848.","DOI":"10.1371\/journal.pone.0089848"},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0405","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exphem.2012.09.002","article-title":"Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma","volume":"41","author":"Zhang","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bioorg.2024.108073_b0410","doi-asserted-by":"crossref","unstructured":"L. Pan, C. Cheng, P. Duan, K. Chen, Y. Wu, Z. Wu, XPO1\/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor Verdinexor, J Exp Clin Cancer Res. 40(1) (2021) 255, https:\/\/doi.org\/ 10.1186\/s13046-021-02044-z.","DOI":"10.1186\/s13046-021-02044-z"},{"key":"10.1016\/j.bioorg.2024.108073_b0415","doi-asserted-by":"crossref","unstructured":"E.M. Vlodaver, M.K. Keating, W.A. Bidot, D.S. Bruyette, W.S. Rosenkrantz, Efficacy of verdinexor for the treatment of na\u00efve canine epitheliotropic cutaneous T-cell lymphoma: An open-label pilot study, Vet Dermatol. 29(2024 Jul), https:\/\/doi.org\/10.1111\/vde.13280.","DOI":"10.1111\/vde.13280"},{"key":"10.1016\/j.bioorg.2024.108073_b0420","doi-asserted-by":"crossref","unstructured":"D.G. Widman, S. Gornisiewicz, S. Shacham, S. Tamir, In vitro toxicity and efficacy of Verdinexor, an exportin 1 inhibitor, on opportunistic viruses affecting immunocompromised individuals, Plos One. 13 (2018), https:\/\/doi.org\/ 10.1371\/journal.pone.0200043.","DOI":"10.1101\/351825"},{"issue":"14","key":"10.1016\/j.bioorg.2024.108073_b0425","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","article-title":"CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity","volume":"118","author":"Sakakibara","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108073_b0430","doi-asserted-by":"crossref","unstructured":"N. Saito, K. Sakakibara, T. Sato, J.M. Friedman, D.D. Kufe VonHoff, T. Kawabe, CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway, Mol Cancer Ther. 13(12) (2014) 3013-23. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0064.","DOI":"10.1158\/1535-7163.MCT-14-0064"},{"issue":"Supplement4","key":"10.1016\/j.bioorg.2024.108073_b0435","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1016\/j.annonc.2020.08.678","article-title":"Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed\/refractory solid tumours","volume":"31","author":"Wang","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.bioorg.2024.108073_b0440","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1016\/j.apsb.2024.04.014","article-title":"Antitumor activity and low gastrointestinal toxicity of a novel selective inhibitor of nuclear export, SZJK-0421, in multiple myeloma","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.bioorg.2024.108073_b0445","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/tra.12802","article-title":"Discovery and biological evaluation of a small-molecule inhibitor of CRM1 that suppresses the growth of triple-negative breast cancer cells","volume":"22","author":"Gao","year":"2021","journal-title":"Traffic"},{"issue":"8","key":"10.1016\/j.bioorg.2024.108073_b0450","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1021\/acs.jmedchem.9b01663","article-title":"Small-Molecule Antagonist Targeting Exportin-1 via Rational Structure-Based Discovery","volume":"63","author":"Tian","year":"2020","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2024.108073_b0455","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0460","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.leukres.2014.10.003","article-title":"CRM1 as a new therapeutic target for non-Hodgkin lymphoma","volume":"39","author":"Han","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bioorg.2024.108073_b0465","doi-asserted-by":"crossref","unstructured":"R.A. Salas Fragomeni, H.W. Chung, Y. Landesman, W. Senapedis, J.R. Saint-Martin, H. Tsao, et al. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma, Mol Cancer Ther. 12(7) (2013) 1171-9, https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-1171.","DOI":"10.1158\/1535-7163.MCT-12-1171"},{"issue":"10","key":"10.1016\/j.bioorg.2024.108073_b0470","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1021\/acs.jmedchem.0c01675","article-title":"Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1","volume":"64","author":"Lei","year":"2021","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2024.108073_b0475","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1021\/acs.jmedchem.3c00549","article-title":"Discovery of Aminoratjadone Derivatives as Potent Noncovalent CRM1 Inhibitors","volume":"66","author":"Jian","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2024.108073_b0480","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/cells4030538","article-title":"Structural Basis of Targeting the Exportin CRM1 in Cancer","volume":"4","author":"Dickmanns","year":"2015","journal-title":"Cells."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2024.108073_b0485","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.febslet.2004.08.056","article-title":"Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms","volume":"576","author":"Meissner","year":"2004","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2024.108073_b0490","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","article-title":"Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1","volume":"110","author":"Sun","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.bioorg.2024.108073_b0495","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/j.clml.2018.07.149","article-title":"Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)","volume":"18","author":"Jagannath","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.bioorg.2024.108073_b0500","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12916-022-02305-4","article-title":"Selinexor plus low-dose dexamethasone in Chinese patients with relapsed\/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.bioorg.2024.108073_b0505","doi-asserted-by":"crossref","unstructured":"H. Hashmi, K. Green, The 'comeback' of Selinexor: From toxic to tolerable, Curr Probl Cancer. 46 (2022) 100789, https:\/\/doi.org\/ 10.1016\/j.currproblcancer.2021.100789.","DOI":"10.1016\/j.currproblcancer.2021.100789"},{"key":"10.1016\/j.bioorg.2024.108073_b0510","doi-asserted-by":"crossref","unstructured":"T. Kashyap, C. Argueta, A. Aboukameel, T.J. Unger, B. Klebanov, R. M, et al. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death, Oncotarget. 7(48) (2016) 78883-78895, https:\/\/doi.org\/ 10.18632\/oncotarget.12428.","DOI":"10.18632\/oncotarget.12428"},{"issue":"22","key":"10.1016\/j.bioorg.2024.108073_b0515","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V128.22.3298.3298","article-title":"Synergistic Anti-Tumor Effect of KPT-8602, a Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, and Panobinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor in Multiple Myeloma","volume":"128","author":"Argueta","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bioorg.2024.108073_b0520","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/ph14111131","article-title":"Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones","volume":"14","author":"Gargantilla","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"Supplement 1","key":"10.1016\/j.bioorg.2024.108073_b0525","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood-2022-169765","article-title":"XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies","volume":"140","author":"Kruer","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.bioorg.2024.108073_b0530","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/blood-2018-99-116500","article-title":"E2F1 Is a Biomarker of Selinexor Resistance in Relapsed\/Refractory Multiple Myeloma Patients","volume":"132","author":"Lagana","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2024.108073_b0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114305","article-title":"E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1","volume":"160","author":"Kwanten","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"Supplement 1","key":"10.1016\/j.bioorg.2024.108073_b0540","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1182\/blood-2021-149701","article-title":"Single Cell RNA Sequencing in Patients Enrolled in a Selinexor Clinical Trial Reveals Overexpression of Alternative Nuclear Export Pathways Associated with Resistance to Selinexor in Refractory Multiple Myeloma","volume":"138","author":"Cohen","year":"2021","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.bioorg.2024.108073_b0545","doi-asserted-by":"crossref","first-page":"68842","DOI":"10.18632\/oncotarget.11995","article-title":"Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export","volume":"7","author":"Neggers","year":"2016","journal-title":"Oncotarget"},{"issue":"Supplement 1","key":"10.1016\/j.bioorg.2024.108073_b0550","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1182\/blood-2023-190030","article-title":"Active STAT3 Prevents Selinexor-Induced Caspase-Independent Apoptosis in Multiple Myeloma","volume":"142","author":"Mack","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bioorg.2024.108073_b0555","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s41589-024-01586-5","article-title":"Targeting the chromatin binding of exportin-1 disrupts NFAT and T cell activation","volume":"20","author":"Chen","year":"2024","journal-title":"Nat. Chem. Biol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824009787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T21:04:24Z","timestamp":1736456664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824009787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":111,"alternative-id":["S0045206824009787"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108073","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting XPO1 for fighting relapsed\/refractory diseases: The research progress of XPO1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.108073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108073"}}